Sign In
Buy VRAX
$0.155
-0.0081 (-4.97%)
At Close: Jun 23, 2026
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
07:30am, Tuesday, 26'th May 2026
LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
07:34am, Tuesday, 14'th Apr 2026
Virax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite i
What's Behind The Jump In Virax Biolabs Stock?
10:38am, Tuesday, 31'st Mar 2026
Virax Biolabs said that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
07:34am, Tuesday, 31'st Mar 2026
LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update
02:55am, Wednesday, 11'th Mar 2026
Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 55,704 shares,
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 67.6% in February
03:22am, Thursday, 26'th Feb 2026
Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 21,126 shares, a drop o
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 5.3% – Here’s What Happened
04:13am, Saturday, 21'st Feb 2026
Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report)'s stock price dropped 5.3% on Friday. The company traded as low as $0.21 and last traded at $0.2130. Approximately 93,300 shares were trade
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
01:01pm, Thursday, 15'th Jan 2026
Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)
03:30am, Monday, 08'th Dec 2025
Virax Biolabs Group (NASDAQ: VRAX - Get Free Report) and MannKind (NASDAQ: MNKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two bus
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
04:05pm, Thursday, 04'th Dec 2025
Extends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA
Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally
02:29am, Thursday, 04'th Dec 2025
VRAX shares fell 12.79% in after-hours trading following a $5 million private placement announcement.
Virax Biolabs Group Limited Announces $5 Million Private Placement
01:53pm, Wednesday, 03'rd Dec 2025
LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research an
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
07:34am, Wednesday, 03'rd Dec 2025
Virax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a ser
LONDON , Nov. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and dia
LONDON , Aug. 26, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection and diagnostics,
